Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is available in delayed-release oral tablets/suspension and IV formulations.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Short-term treatment of GERD symptoms (off-label use common for stress ulcer prophylaxis).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO/IV once daily for 8 weeks; may extend another 8 weeks if not healed. Maintenance: 40 mg PO daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO/IV twice daily. Doses up to 240 mg/day have been used; individualize based on acid output titration.
* **Stress Ulcer Prophylaxis (Off-label):** 40 mg IV daily.
## Pediatric Dosing
* **Erosive Esophagitis (5 years and older):**
* Weight ≥15 kg to <40 kg: 20 mg PO once daily.
* Weight ≥40 kg: 40 mg PO once daily.
* **Safety/Efficacy:** Dosing for durations >8 weeks has not been established in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** In severe hepatic impairment (Child-Pugh C), consider dose reduction or alternate-day dosing, as clearance is reduced.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia (with long-term use), vitamin B12 deficiency (long-term use), interstitial nephritis, and increased risk of bone fractures (hip, wrist, spine) with high-dose/long-term therapy.
## Key Drug Interactions
* **pH-dependent drugs:** May decrease absorption of atazanavir, nelfinavir, and certain azole antifungals (e.g., ketoconazole).
* **Methotrexate:** Potential increase in serum methotrexate levels, particularly in high-dose therapy.
* **Warfarin:** Potential for increased INR/PT; monitor closely when initiating or discontinuing PPI therapy.
## Monitoring
* **Clinical:** Resolution of gastric symptoms.
* **Long-term:** Serum magnesium (especially if on diuretics or digoxin), vitamin B12 levels, and monitor for signs of *C. difficile* infection.
* **Bone Density:** Evaluate fracture risk in patients requiring long-term/high-dose treatment.
## Clinical Pearls
* **Administration:** Tablets should be swallowed whole; do not crush or chew. IV administration should be a 15-minute infusion or a 2-minute slow bolus (varies by institutional protocol; follow local stability guidelines for IV preparations).
* **Discontinuation:** Chronic use may lead to rebound acid hypersecretion upon withdrawal; taper PPI slowly if long-term use is no longer indicated.
* **Time to Effect:** Acid suppression begins after the first dose, but maximal inhibition requires 3–5 days of daily dosing.
***
**Educational Disclaimer:** This summary is for informational purposes only and does not constitute medical advice. Always verify current prescribing information, dosing protocols, and patient-specific contraindications via institutional resources or official FDA-approved labels before administering medication.
